NEW YORK, Jan. 22, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.
The investigation concerns whether Advaxis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On January 21, 2015, SeekingAlpha published an article asserting that Advaxis misstated the tumor response data for its ADXS-HPV drug in a recent corporate presentation, overstating its effectiveness in shrinking tumors. The article also alleges that the Company has misled investors concerning the design of its planned Phase 3 trial.
On this news, shares of Advaxis fell $3.39 per share or over 28% to close at $8.37 per share on January 21, 2015.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
SOURCE Pomerantz LLP